COMP <GO>
IONS vs RYTM // PIOTROSKI F-SCORE QUALITY
Ionis Pharmaceuticals Inc. (NASDAQ) VS. Rhythm Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: IONS 6
— RYTM 5
■ METRIC PARITY
LAST: $41.24 (-5.24%) • MKT CAP: $7.23B
piotroski-score
5/9
LAST: $93.44 (+0.94%) • MKT CAP: $6.37B
piotroski-score
5/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IONS VS. RYTM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IONS | RYTM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 89.70% | +6.30 | IONS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -20.90% | -29.60% | +8.70 | IONS | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -4.34% | -1.82% | -2.52 | RYTM | /fcf-yield <GO> |
| Operating Margin | -40.40% | -60.00% | +19.60 | IONS | /operating-margins <GO> |
| Net Profit Margin | -40.40% | -0.10% | -40.30 | RYTM | /net-margins <GO> |
| Revenue Growth (YoY) | 33.80% | 45.80% | -12.00 | RYTM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.08 | 14.33 | -13.25 | RYTM | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 5/9 | 5/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.6 | 50.0 | -6.40 | RYTM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.09 | 0.96 | +0.13 | IONS | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 33.0x | -11.00 | IONS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.23B | $6.37B | $858.7M | IONS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IONS REV | RYTM REV | IONS GROSS % | RYTM GROSS % | IONS FCF | RYTM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $943.7M | $189.8M | 98.3% | 89.7% | -$320.0M | -$116.6M |
| FY 2024 | $705.1M | $130.1M | 98.4% | 89.7% | -$546.2M | -$113.9M |
| FY 2023 | $787.6M | $77.4M | — | — | -$343.0M | -$139.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IONS // BETA 1.09
RYTM // BETA 0.96